Intrahepatic-artery infusion of cis-diamminedichloroplatinum (II) and 5-fluorouracil in primary or metastatic liver cancer
Koga, S.; Maeta, M.; Wakatsuki, T.; Ikeda, Y.; Inoue, Y.; Ishiguro, M.
Gan to Kagaku Ryoho. Cancer and ChemoTherapy 14(2): 404-410
1987
ISSN/ISBN: 0385-0684 PMID: 3813570 Document Number: 286420
Eight hepatocellular cancer patients and eighteen metastatic liver cancer patients were treated with intrahepato-arterial infusion of CDDP (cis-diamminedichloro-platinum II) plus 5-FU (5-fluorouracil); CDDP (0.8-1.0 mg/kg) was given once every 7 or 10-14 days, while 5-FU (250-100 mg/day) was infused daily. A partial response was obtained in 5 of 8 patients with primary liver cancer and in 9 of 14 evaluable patients with metastatic liver cancer. However, severe complications due to bone marrow suppression were observed in 4 patients, 3 of whom died of septicemia and one of enterocolitis. This combined intra-hepato-arterial chemotherapy exerts a synergistic anticancer effect on malignant liver tumors, although the bone marrow suppression associated with it remains to be overcome.